[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:extragonadal-yolk-sac-tumors":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":15,"states":16},"Extragonadal Yolk Sac Tumors",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06427941","A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors",[11],"Phase 1","RECRUITING","2026-08-26T02:18:47.742071Z","2026-05-05T02:43:29.729672Z",[],[]]